



*Pravin Chandak  
Associates*

Chartered Accountants

## INDEPENDENT AUDITOR'S REPORT

**TO THE MEMBERS OF SAROJA PHARMA INDUSTRIES INDIA LIMITED  
(FORMERLY KNOWN AS SAROJA PHARMA INDUSTRIES INDIA PRIVATE  
LIMITED)**

### **Report on the Audit of the Financial Statements**

#### **Opinion**

We have audited the accompanying standalone financial statements of **Saroja Pharma Industries India Limited (Formerly known as Saroja Pharma Industries India Private Limited** ("the Company"), which comprise the Balance Sheet as at March 31, 2023, the Statement of Profit and Loss and statement of cash flow for the year ended on that date, and a summary of the significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at 31 March 2023 and its profit / (loss) and statement of cash flow for the year ended on that date.

#### **Basis for Opinion**

We conducted our audit of the financial statements in accordance with the Standards on Auditing specified under section 143(10) of the Act (SAs). Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Statements* section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the independence requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules made thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the financial statements.

#### **Management's Responsibility for the Financial Statements**

The Company's Board of Directors is responsible for the matters stated in section 134 (5) of the Act with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance and statement of cash flow of the Company in accordance with the AS and other accounting principles generally accepted in India. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting



403, 4th Floor & 702/703, 7th Floor,  
New Swapnalok CHS Ltd.,  
Natakwala Lane, Borivali (West),  
Mumbai - 400 092. Tel : 2801 6119  
Email : info@pravinca.com  
Website : www.pravinca.com

frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are responsible for overseeing the Company's financial reporting process.


### **Auditor's Responsibilities for the Audit of the Financial Statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion.

Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are



inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the standalone financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

### **Report on Other Legal and Regulatory Requirements**

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Companies Act, 2013, we give in the **Annexure A** statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.
2. As required by Section 143(3) of the Act, based on our audit we report that:
  - a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
  - b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
  - c) The Balance Sheet, the Statement of Profit and Loss, statement of cash flow including Statement of Changes in Equity dealt with by this Report are in agreement with the relevant books of account.
  - d) In our opinion, the aforesaid financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
  - e) On the basis of the written representations received from the directors as on March 31, 2023 taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2023 from being appointed as a director in terms of Section 164 (2) of the Act.
  - f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in **Annexure B**;
  - g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, as amended in our opinion and to the best of our information and according to the explanations given to us:
    - i. The Company has disclosed the impact of pending litigations, if any on its financial position in its standalone financial statements.
    - ii. The Company has made provision, as required under the applicable law or accounting standards, for material foreseeable losses, if any, on long-term contracts including derivative contracts.



- iii. There has been no delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the Company.
- iv. (a) The management has represented that, to the best of it's knowledge and belief, other than as disclosed in the notes to the accounts, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;
- (b) The management has represented, that, to the best of it's knowledge and belief, other than as disclosed in the notes to the accounts, no funds have been received by the company from any person(s) or entity(ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and
- (c) Based on audit procedures which we considered reasonable and appropriate in the circumstances, nothing has come to their notice that has caused them to believe that the representations under sub-clause (a) and (b) contain any material mis-statement.
- v. The company has not declared or paid any dividend during the year in contravention of the provisions of section 123 of the Companies Act, 2013.

With respect to the matter to be included in the Auditors' Report under Section 197(16) of the Act, in our opinion and according to the information and explanations given to us, the limit prescribed by section 197 for maximum permissible managerial remuneration is not applicable to a private limited company.

**For Pravin Chandak & Associates.**  
**Chartered Accountants**  
**Firm's registration number: 116627W**

**Pravin Chandak**  
**Partner**  
**Membership number: 049391**  
**Place: Mumbai**



**Date : 17/05/2023**  
**UDIN: 23049391BGRNRN6645**



## ANNEXURE – A Report under the Companies (Auditor’s Report) Order, 2020

(Referred to in paragraph 1 under ‘Report on other legal and regulatory requirements’ section of our report to the members of **Saroja Pharma Industries India Limited** (Formerly known as **Saroja Pharma Industries India Private Limited** of even date)

In terms of the information and explanations sought by us and given by the company and the books and records examined by us in the normal course of audit and to the best of our knowledge and belief, we state that: -

### (I)


- a. The Company has maintained proper records showing full particulars including quantitative details and situation of Property, Plant and Equipment. The Company has proper records showing full particulars of intangible assets
- b. The Company has a program of verification to cover all the items of fixed assets in a phased manner over a period of once in a year, which, in our opinion, is reasonable having regard to the size of the Company and the nature of its assets.

Pursuant to the program, certain fixed assets were physically verified by the management during the year. According to the information and explanations given to us, no material discrepancies were noticed on such verification.

- c. We report that, the title in respect of land appears under immovable, disclosed in the financial statements included under Property, Plant and Equipment are held in the name of the Company as at the balance sheet date.
- d. The company has not revalued its Property, Plant and Equipment during the year. Therefore, the provisions of Clause (i)(d) of paragraph 3 of the order are not applicable to the company.
- e. No proceedings have been initiated or are pending against the company for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988) and rules made thereunder. Therefore, the provisions of Clause (i)(e) of paragraph 3 of the order are not applicable to the company

### (II)

- a. Physical verification of inventory has been conducted at reasonable intervals by the management and in our opinion, the coverage and procedure of such verification by the management is appropriate; We have not found any discrepancies of 10% or more in the aggregate for each class of inventory.
- b. The company has been sanctioned working capital limits in excess of five crore, in aggregate, from banks or financial institutions on the basis of security of current assets;



quarterly statements filed by the company with such banks or financial institutions are in agreement with the books of account of the company except follow as under:

| Quarter    | Name of bank   | Nature of Current Assets          | Nature of Discrepancies | Amount as per statement | Amount as per Books of Account | Difference | Reason for differences, as explained by the management  |
|------------|----------------|-----------------------------------|-------------------------|-------------------------|--------------------------------|------------|---|
| June 2022  | Bank of Baroda | Inventories and Trade Receivables | Excess report           | 46,44,736               | 45,39,736                      | 1,05,000   | Change in value / amount after submission of statement to Bank due to Audit Change in value / amount after submission of statement to Bank due to Audit |
| March 2023 | Bank of Baroda | Inventories and Trade Receivables | Excess report           | 3,86,61,870             | 3,86,58,224                    | 3,647      |   |

- ( III ) During the year, the company has not made any investments, provided any guarantee or security or granted any loans or advances in the nature of loans, secured or unsecured, to companies, firms, Limited Liability Partnerships or any other parties,
- ( IV ) In our opinion and according to information and explanation given to us, the company has not granted any loans or provided any guarantees or given any security or made any investments to which the provision of section 185 and 186 of the Companies Act, 2013. Accordingly, paragraph 3 (iv) of the order is not applicable.
- ( V ) The Company has not accepted any amounts which are deemed to be deposits and the provisions of sections 73 to 76 or any other relevant provisions of the Companies Act and the rules made thereunder.



(VI) As explained to us, the central Government of India has not specified the maintenance of cost records under sub-section (1) of section 148 of the Act for any of products of the company. Therefore, the provisions of clause (vi) of paragraph 3 of the order are not applicable to the company..

(VII)

a. According to the information and explanations given to us and on the basis of our examination of the records of the Company, amounts deducted/ accrued in the books of account in respect of undisputed statutory dues including provident fund, employees' state insurance, income-tax, sales- tax, service tax, goods and service tax, duty of customs, duty of excise, value added tax, cess and other material statutory dues have been generally regularly deposited during the year by the company with the appropriate authorities.


According to the information and explanations given to us, no undisputed amounts payable in respect of provident fund, employees' state insurance, income-tax, sales- tax, service tax, goods and service tax, duty of customs, duty of excise, value added tax, cess and other material statutory dues were in arrears as at reporting date for a period of more than six months from the date they became payable

b. According to the information and explanations given to us and the records of the company examined by us, there are no dues of income-tax, sales- tax, service tax, goods and service tax, duty of customs, duty of excise and value added tax which have not been deposited on account of any dispute.

(VIII) In our opinion and according to the information and explanations given to us, there is no transaction not recorded in the books of account which have been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (43 of 1961).

(IX)

- a. In our opinion and according to the information and explanations given to us, the Company has not defaulted in repayment of any loan or other borrowings or any interest due thereon to any lender.
- b. In our opinion and according to the information and explanations given to us, the company has not been a declared willful defaulter by any bank or financial institution or other lender
- c. The term loans were applied for the purpose which they were obtained
- d. In our opinion and according to the information and explanations given to us, there are no funds raised on short term basis which have been utilized for long term purposes.
- e. In our opinion and according to the information and explanations given to us, the company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries, associates or joint ventures.
- f. In our opinion and according to the information and explanations given to us, the company



has not raised loans during the year on the pledge of securities held in its subsidiaries, joint ventures or associate companies

**( X )**

- a. The Company has not raised money by way of initial public offer or further public offer (including debt instruments). Therefore, the provisions of Clause (x)(a) of paragraph 3 of the order are not applicable to the Company
- b. The Company has not made any preferential allotment of shares. Therefore, the provisions of Clause (x)(b) of paragraph 3 of the order are not applicable to the Company

**( XI )**

- a. We have not noticed any case of fraud by the company or any fraud on the Company by its officers or employees during the year. The management has also not reported any case of fraud during the year
- b. During the year no report under sub-section (12) of section 143 of the Companies Act has been filed by the auditors in Form ADT-4 as prescribed under rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government.
- c. As auditor, we did not receive any whistle- blower complaint during the year.

**( XII )** The company is not a Nidhi Company. Therefore, the provisions of Clause (xii) of paragraph 3 of the order are not applicable to the Company.

**( XIII )** As per the information and explanations received to us all transactions with the related parties are in compliance with sections 177 and 188 of Companies Act where applicable, and the details have been Disclosed in the financial statements, etc., as required by the applicable accounting standards. Identification of related parties were made and provided by the management of the company

**( XIV )** The company is not covered by section 138 of the Companies Act, 2013, related to appointment of internal auditor of the company. Therefore, the company is not required to appoint any internal auditor. Therefore, the provisions of Clause (xiv) of paragraph 3 of the order are not applicable to the Company.

**( XV )** According to the information and explanations given to us and based on our examination of the records of the company, the company has not entered into non-cash transactions with directors or persons connected with them. Accordingly, paragraph 3(xv) of the order is not applicable.

**( XVI )**

- a. The Company is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934.
- b. The company has not conducted any Non-Banking Financial or Housing Finance activities





during the year.

- c. The company is not a Core Investment Company (CIC) as defined in the regulations made by the Reserve Bank of India
- d. As per the information and explanations received, the group does not have any CIC as part of the group.

( XVII ) The company has not incurred cash loss in current financial year as well in immediately preceding financial year.

( XVIII ) There has been no resignation of the previous statutory auditors during the year.

( XIX ) On the basis of the financial ratios, ageing and expected dates of realization of financial assets and payment of financial liabilities, other information accompanying the financial statements, the auditor's knowledge of the Board of Directors and management plans, we are of the opinion that no material uncertainty exists as on the date of the audit report that company is capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date.


( XX ) The provision of section 135 of the Companies Act, relating to Corporate Social Responsibility are not applicable to the company.

( XXI ) The company has not made investments in subsidiary or associate company. Therefore, the company is not required to prepare consolidated financial statement.

**For Pravin Chandak & Associates.**

**Chartered Accountants**

**Firm's registration number: 116627W**



**Pravin Chandak**

**Partner**

**Membership number: 049391**

**Date : 17/05/2023**

**UDIN: 23049391BGRNRN6645**



## **ANNEXURE – B Report under the Companies (Auditor's Report) Order, 2020**

Referred to in paragraph 3 (f) under 'Report on Other Legal and Regulatory Requirements' section of our report to the Members of **SAROJA PHARMA INDUSTRIES INDIA LIMITED (FORMERLY KNOWN AS SAROJA PHARMA INDUSTRIES INDIA PRIVATE LIMITED)**

Report on the Internal Financial Controls under Clause (i) of Subsection 3 of Section 143 of the Companies Act, 2013 ("the Act").

We have audited the internal financial controls over financial reporting **SAROJA PHARMA INDUSTRIES INDIA LIMITED (FORMERLY KNOWN AS SAROJA PHARMA INDUSTRIES INDIA PRIVATE LIMITED)** ("the Company") as of March 31, 2023 in conjunction with our audit of the Financial Statements of the Company for the financial year ended on that date.

### **Management's Responsibility for Internal Financial Controls**

The Company's Management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to the Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

### **Auditor's Responsibility**

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") and the Standards on Auditing as specified under section 143(10) of the Companies Act, 2013, to the



extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

### **Meaning of Internal Financial Controls Over Financial Reporting**

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.

A company's internal financial control over financial reporting includes those policies and procedures that

- (1) pertains to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company;
- (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and



(3) Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

### **Inherent Limitations of Internal Financial Controls Over Financial Reporting**

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

### **Opinion**

In our opinion, to the best of our information and according to the explanations given to us the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2023, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

**For Pravin Chandak & Associates.**

**Chartered Accountants**

**Firm's registration number:**

**Pravin Chandak**

**Partner**

**Membership number:**

**Date : 17/05/2023**

**UDIN: 23049391BGRNRN6645**





**SAROJA PHARMA INDUSTRIES INDIA LTD**  
**( FORMERLY KNOWN AS SAROJA PHARMA INDUSTRIES INDIA PVT LTD)**  
**BALANCE SHEET AS AT 31ST MARCH 2023**  
**CIN: U24110MH2019PLC319508**

| Particulars                                  | Note No. | As at 31.03.2023    | As at 31.03.2022    |
|--|----------|---------------------|---------------------|
| <b>I. EQUITY AND LIABILITIES</b>             |          |                     |                     |
| <b>1 Shareholders' Funds</b>                 |          |                     |                     |
| (a) Share Capital                            | 2        | 2,93,56,860         | 22,58,220           |
| (b) Reserves and Surplus                     | 3        | 2,15,09,041         | 3,80,01,535         |
| <b>2 Non-Current liabilities</b>             |          |                     |                     |
| (a) Long-term Borrowings                     | 4        | 2,81,15,187         | 1,69,71,140         |
| (b) Deferred Tax Liabilities (Net)           | 5        | 1,25,974            | 33,787              |
| (c) Long-term Provisions                     |          |                     | -                   |
| <b>3 Current Liabilities</b>                 |          |                     |                     |
| (a) Short-term Borrowings                    | 6        | 7,37,71,311         | 4,44,16,362         |
| (b) Trade Payables                           | 7        | 5,86,29,594         | 5,30,51,932         |
| (c) Other Current Liabilities                | 8        | 1,73,028            | 2,41,694            |
| (d) Short-term Provisions                    | 9        | 17,17,638           | 1,44,177            |
| <b>TOTAL</b>                                 |          | <b>21,33,98,633</b> | <b>15,51,18,847</b> |
| <b>II. ASSETS</b>                            |          |                     |                     |
| <b>1 Non-current Assets</b>                  |          |                     |                     |
| (a) Property, Plant & Equipment & Intangible | 10       |                     |                     |
| (i) Property, Plant & Equipment              |          | 2,21,37,707         | 34,16,262           |
| (ii) Capital Work-in-progress                |          | 1,78,87,716         | -                   |
| (iii) Intangible Assets                      |          | 13,902              | 25,584              |
| (b) Non- Current Investments                 | 11       | 14,19,059           | 3,92,166            |
| (c) Long-term Loans and Advances             | 12       | 1,04,49,230         | 3,66,600            |
| (d) Deferred Tax Asset (Net)                 | 5        | -                   |                     |
| <b>2 Current Assets</b>                      |          |                     |                     |
| (a) Inventories                              | 13       | 3,86,58,224         | 46,65,229           |
| (b) Trade Receivables                        | 14       | 11,10,78,412        | 13,97,98,544        |
| (c) Cash and Cash Equivalents                | 15       | 36,41,319           | 26,46,361           |
| (d) Short Term Loans & Advances              | 16       | 4,42,446            | 24,66,100           |
| (e) Other Current Assets                     | 17       | 76,70,618           | 13,42,001           |
| <b>TOTAL</b>                                 |          | <b>21,33,98,633</b> | <b>15,51,18,847</b> |

Significant Accounting Policies & Notes on Accounts

For Pravin Chandak & Associates

Chartered Accountant

Firm Regn No: 116627W

Pravin Chandak

Partner

Membership No.:049391

Place: Mumbai

Date: 17/05/2023

For & on behalf of the Board of Directors

SAROJA PHARMA INDUSTRIES INDIA LTD

(FORMERLY KNOWN AS SAROJA PHARMA INDUSTRIES INDIA PVT LTD)

Biju G Nair


Managing Director

DIN: 08330223

Manish D Kamble

Wholetime Director

DIN: 08330224



**SAROJA PHARMA INDUSTRIES INDIA LTD**  
**( FORMERLY KNOWN AS SAROJA PHARMA INDUSTRIES INDIA PVT LTD)**  
**STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED 31ST MARCH 2023**  
**CIN: U24110MH2019PLC319508**

| Particulars                            | Note No. | For the year ended 31.03.2023 | For the year ended 31.03.2022 |
|--|----------|-------------------------------|-------------------------------|
| Revenue from operations                | 18       | 50,19,31,562                  | 55,63,25,325                  |
| Other income                           | 19       | 15,77,068                     | 32,41,785                     |
| <b>Total Income</b>                    |          | <b>50,35,08,630</b>           | <b>55,95,67,110</b>           |
| <b>Expenses:</b>                       |          |                               |                               |
| Cost of Materials Consumed             | 20       | 48,69,52,465                  | 50,13,10,710                  |
| (Increase)/Decrease in Inventories     | 21       | -3,39,92,995                  | 18,95,771                     |
| Employee Benefit Expenses              | 22       | 1,36,76,006                   | 1,14,28,655                   |
| Finance Cost                           | 23       | 1,31,88,812                   | 80,13,297                     |
| Depreciation and Amortization Expenses |          | 6,66,468                      | 4,56,265                      |
| Other Expenses                         | 24       | 81,02,824                     | 2,06,69,325                   |
| <b>Total Expenses</b>                  |          | <b>48,85,93,580</b>           | <b>54,37,74,023</b>           |
| <b>Profit before Exceptional Items</b> |          | <b>1,49,15,050</b>            | <b>1,57,93,087</b>            |
| Exceptional Items                      |          |                               |                               |
| Prior Period Items                     |          |                               |                               |
| <b>Profit/(Loss) before Tax</b>        |          | <b>1,49,15,050</b>            | <b>1,57,93,087</b>            |
| <b>Tax Expenses:</b>                   |          |                               |                               |
| Current Tax                            |          | 42,16,715                     | 43,75,978                     |
| Mat Credit Entitlement                 |          |                               |                               |
| Deferred Tax Provision / (Reversal)    |          | 92,187                        | -15,869                       |
| <b>Profit/(Loss) for the year</b>      |          | <b>1,06,06,148</b>            | <b>1,14,01,240</b>            |
| <b>Earnings per equity share:</b>      |          |                               |                               |
| Basic (in Rs.)                         |          | 17.55                         | 68.72                         |
| Diluted (in Rs.)                       |          | 17.55                         | 68.72                         |

Significant Accounting Policies & Notes on Accounts  
For Pravin Chandak & Associates  
Chartered Accountant  
Firm Regn No: 116627W

For & on behalf of the Board of Directors  
SAROJA PHARMA INDUSTRIES INDIA LTD  
(FORMERLY KNOWN AS SAROJA PHARMA  
INDUSTRIES INDIA PVT LTD)

Pravin Chandak  
Partner  
Membership No.:049391  
Place: Mumbai  
Date: 17/05/2023

Biju G Nair  
Managing Director  
DIN: 08330223

Manish D Kamble  
Wholetime Director  
DIN: 08330224



**SAROJA PHARMA INDUSTRIES INDIA LTD**  
**( FORMERLY KNOWN AS SAROJA PHARMA INDUSTRIES INDIA PVT LTD)**  
**CASH FLOW STATEMENT FOR THE YEAR ENDED 31ST MARCH 2023**  
**CIN: U24110MH2019PLC319508**

| Particulars  | For the Year ended 31.03.2023 | For the Year ended 31.03.2022 |
|--|-------------------------------|-------------------------------|
| <b>A CASH FLOW FROM OPERATING</b>                              |                               |                               |
| <b>B</b> Net Profit before tax                                 |                               |                               |
| <b>C</b> Depreciation & Amortisation                           | 1,49,15,048                   | 1,57,93,087                   |
| Finance Cost   | 6,66,468                      | 4,56,265                      |
| Interest /Dividend Income                                      | 1,31,88,812                   | 80,13,297                     |
| <b>Operating Profit before Working Capital</b>                 | <b>-1,28,751</b>              | <b>-98,502</b>                |
| <b>Adjusted for:</b>   | <b>2,86,41,577</b>            | <b>2,41,64,147</b>            |
| (Increase)/Decrease in trade receivables                       | 2,87,20,132                   | -6,75,63,410                  |
| (Increase)/Decrease in other assets                            | -63,28,617                    | -16,12,071                    |
| Increase/(Decrease) in other liabilities                       | 15,04,795                     | -7,96,916                     |
| Increase/(Decrease) in trade payables                          | 55,77,662                     | 1,15,49,489                   |
| Short term loans and advances                                  | 20,23,654                     | -                             |
| Changes in provisions  | -                             | -                             |
| (Increase)/Decrease in inventories                             | -3,39,92,995                  | 18,95,771                     |
| <b>Cash Generated From Operations</b>                          |                               |                               |
| Payment of Income Tax (Net of Refund)                          | -42,16,715                    | -43,75,978                    |
| <b>Net cash generated/ (used in) from operating activities</b> | <b>2,19,29,493</b>            | <b>-3,67,38,968</b>           |
| <b>CASH FLOW FROM INVESTING</b>                                |                               |                               |
| Purchase of Property, Plant & Equipment                        | -3,72,63,947                  | -30,23,123                    |
| Advance for Factory plot                                       | -1,00,82,630                  | -61,000                       |
| Purchase of Shares   |                               |                               |
| Purchase of Investment   | -10,26,893                    | -3,67,166                     |
| Interest Income  | 1,28,751                      | 98,502                        |
| <b>Net Cash used in Investing Activities (B)</b>               | <b>-4,82,44,719</b>           | <b>-33,52,787</b>             |
| <b>CASH FLOW FROM FINANCING</b>                                |                               |                               |
| Proceeds from issue of shares                                  |                               | 1,94,99,132                   |
| Share premium  |                               | -                             |
| Proceeds from issue of Bonus shares                            |                               | -                             |
| Transfer of Balance of P/L a/c. of transferor co.              |                               | -                             |
| Proceeds from short term borrowing                             |                               | 3,12,10,989                   |
| Long / Short term loans and advances                           | 4,04,98,996                   | -                             |
| Finance Cost   | -1,31,88,812                  | -80,13,297                    |
| <b>Net Cash used in Financing Activities (C)</b>               | <b>2,73,10,184</b>            | <b>4,26,96,824</b>            |
| <b>Net Increase/(Decrease) in Cash and Cash Equivalents</b>    | <b>9,94,958</b>               | <b>26,05,069</b>              |
| <b>Cash and Cash Equivalents at the beginning of the year</b>  | <b>26,46,361</b>              | <b>41,292</b>                 |
| <b>Cash and Cash Equivalents at the end of the</b>             | <b>36,41,319</b>              | <b>26,46,361</b>              |

Note :-1

| Particulars                                      | As at<br>31.03.2023 | As at<br>31.03.2022 |
|--|---------------------|---------------------|
| a. Balances with banks                           |                     |                     |
| Current Accounts & Term Dep / FD                 | 34,22,812           | 26,36,740           |
| b. Cash on hand (As certified by the management) | 2,18,507            | 9,621               |
| <b>Total</b>                                     | <b>36,41,319</b>    | <b>26,46,361</b>    |

2. The above cash flow statement has been prepared under the indirect method set out in AS-3 issued by the Institute of Chartered Accountants of India.

3. Figures in Brackets represents outflow.

Significant Accounting Policies & Notes on Accounts  
For Pravin Chandak & Associates  
Chartered Accountant  
Firm Regn No: 116627W

Pravin Chandak  
Partner

Membership No.:049391  
Place: Mumbai  
Date: 17/05/2023



For & on behalf of the Board of Directors  
SAROJA PHARMA INDUSTRIES INDIA LTD  
(FORMERLY KNOWN AS SAROJA PHARMA  
INDUSTRIES INDIA PVT LTD)

Biju G Nair  
Managing Director  
DIN: 08330223



Manish D Kamble  
Director  
DIN: 08330224

**SAROJA PHARMA INDUSTRIES INDIA LIMITED**  
**(FORMERLY KNOWN AS SAROJA PHARMA INDUSTRIES INDIA PRIVATE LIMITED)**  
**NOTES FORMING PART OF FINANCIALS STATEMENT FOR THE YEAR ENDED**  
**31<sup>ST</sup> MARCH 2023.**

**NOTES 1 – SIGNIFICANT ACCOUNTING POLICIES**

**1.1 Company Overview**

Saroja Pharma Industries India Limited (previously known as Saroja Pharma Industries India Private Limited) founded by Mr. Biju Nair in January, 2019, is led by Mr. Biju Nair - Managing Director and Mr. Manish Kamble - Director committed to providing the best service deliverance in chemical trading with the best premium pharmaceutical companies in India and abroad for cost effective human and veterinary medicine.

We trade in Pharma API, Pharma Intermediates, Chemicals, Solvents used for pharmaceutical products human and veterinary medicine.

Our mission being providing clientele specification-based approved product at a competitive pricing with hassle free dispatch within INDIA or aboard contributing to cost effectiveness in end product for human and veterinary medicine.

The clientele base has magnified over the last two years since inception contributing us to forge into manufacturing of API Pharma products to further enhance our vision of cost-effective contribution to human and veterinary medicine.

We intend to diversify into manufacturing of API Pharma products within a span of a year to be able to achieve our mission goals. We fully believe in achieving our vision extending to one and all needy in the universe. Our strength being strong presence in Pharma locally as well internationally for procurement and deliverance in accordance to the rules and regulations country of origin (INDIA) and countries of destination around the world. In addition, we have a very strong loyal customer database since our inception till date along with a stable, dedicated, professional knowledge expertise, integrity team in full synchronization with our vision to be the best in the PHARMA API being the main factors of our success.

Our manufacturing unit location an industrial NA was finalized on its connectivity and accessibility being 10-12 km from Samruddhi Highway & 2-3 km from Shirdi – Ghoti Highway along with easy availability of resources in sourcing of labour, water, power etc.

The land area being 16000 sq meter and the project costing is evaluated for 23 Crore's intends to bring a developmental transformation in the area positively.

Our manufacturing unit in this area intends to provide 100 employee job opportunities thereby development of the area (village) by providing opportunities in all of the spheres monetarily and infrastructure and all the support for growth of the village in symphony with our growing phases

SAROJA PHARMA INDUSTRIES INDIA LTD – We believe in Best Committed Express Economical Deliverance in all spheres of transactions internal and external at all levels being executed by our company. Our company further believes and values in building long term relationship every time consistently with one and all interacting through us. The strong culture of our company involves being



A handwritten signature in blue ink, located to the right of the Saroja Pharma Industries India Limited stamp.



transparent and executing well-defined plan of action through daily operations to achieve goals of the organization supported by strategy and structure

- (a) The financial statements are prepared in accordance with Generally Accepted Accounting Principles (Indian GAAP) under the historical cost convention on accrual basis and on principles of going concern. The accounting policies are consistently applied by the Company.
- (b) The financial statements are prepared to comply in all material respects with the Accounting Standards specified under section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014 and provisions of Companies Act, 2013.
- (b) The preparation of the financial statements requires estimates and assumptions to be made that affect the reported amounts of assets and liabilities on the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Differences between the actual results and estimates are recognized in the period in which the results are known / materialize.

### **1.3 Revenue Recognition**

- (a) Revenue is recognized to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured.
- (b) Sales are recognized on accrual basis, and only after transfer of goods or services to the customer.
- (c) Dividend on Investments are recognized on receipt basis.
- (d) Interest income is recognized on a time proportion basis taking into account the amount outstanding and the rate applicable.

### **1.4 Property, Plant & Equipment & Depreciation**


- (a) Fixed Assets are stated at Cost less accumulated depreciation. The Company has capitalized all cost relating to the acquisition and installation of Fixed Assets.
- (b) Depreciation is provided on Fixed Assets on Straight Line Method on the basis of Useful Life as prescribed under Part C of Schedule - II of the Companies Act, 2013.
- (c) Cost of the fixed assets not ready for their intended use at the Balance Sheet date together with all related expenses are shown as Capital Work-in-Progress.

### **1.5 Impairment of Assets**

The carrying amounts of assets are reviewed at each balance sheet date if there is any indication of impairment based on internal/external factors. An impairment loss is recognized wherever the carrying amount of an asset exceeds its recoverable amount. The recoverable amount is the higher of the asset's net selling price and value in use, which is determined by the present value of the estimated future cash flows.

### **1.6 Investments**

Investment classified as long-term investments are stated at cost. Provision is made to recognize any diminution other than temporary in the value of such investments. Current investments are carried at lower of cost and fair value.



### **1.7 Inventories**

Inventories consisting of Raw Materials, Finished Goods are valued at lower of cost and net realizable value.

### **1.8 Employee Benefits**

#### **(A) Defined Contribution Plan:**

Contributions As Per The Employees' Provident Funds And Miscellaneous Provisions Act, 1952 Towards Provident Fund And Pension Fund Are Not Applicable Since Company Does Not Have More Than 20 Employee. There Is No Other Obligation Other Than the Contribution Payable To The Respective Funds.

#### **(b) Defined Benefit Plan:**

Gratuity being unfunded and are provided based on actuarial valuation made at the end of each financial year using the projected unit credit method.

### **1.9 Borrowing Costs**

(a) Borrowing costs that are directly attributable to the acquisition of qualifying assets are capitalized for the period until the asset is ready for its intended use. A qualifying asset is an asset that necessarily takes substantial period of time to get ready for its intended use.

(b) Other Borrowing costs are recognized as expense in the period in which they are incurred.

### **1.10 Taxes on Income**

Tax expense comprises of current tax and deferred tax. Current income tax is measured at the amount expected to be paid to the tax authorities, computed in accordance with the applicable tax rates and tax laws. Deferred Tax arising on account of "timing differences" and which are capable of reversal in one or more subsequent periods is recognized, using the tax rates and tax laws that are enacted or substantively enacted. Deferred tax asset is recognized only to the extent there is reasonable certainty with respect to reversal of the same in future years as a matter of prudence.

### **1.11 Earnings per Share (EPS)**

(a) Basic earnings per share is calculated by dividing the net profit or loss for the period attributable to equity shareholders by the weighted average number of equity shares outstanding during the period.

(b) For the purpose of calculating diluted earnings per share, the net profit or loss for the period attributable to equity shareholders and the weighted average number of shares outstanding during the period are adjusted for the effects of all dilutive potential equity shares.

### **1.12 Prior Period Items**

Prior Period and Extraordinary items and Changes in Accounting Policies having material impact on the financial affairs of the Company are disclosed in financial statements.

### **1.13 Provisions / Contingencies**

(a) Provision involving substantial degree of estimation in measurements is recognized



when there is a present obligation as a result of past events and it is probable that there will be an outflow of resources.

(b) Contingent Liabilities are shown by way of notes to the Accounts in respect of obligations where, based on the evidence

available, their existence at the Balance Sheet date is considered not probable.

(c) A Contingent Asset is not recognized in the Accounts.

#### 1.14 Segment Reporting

##### **A. Business Segments:**

Based on the guiding principles given in Accounting Standard 17 (AS - 17) on Segment Reporting issued by ICAI, the Company has only one reportable Business Segment, which is Chemicals like Thionyl Chloride And Pharmaceuticals intermeddles etc .

Accordingly, the figures appearing in these financial statements relate to the Company's single Business Segment.

##### **B. Geographical Segments:**

The geographical information analyses the Group's revenues by the customer's country of domicile in presenting geographic information segment revenue has been based on the selling location in relation to sales to customers and segment assets are based on geographical location of assets.

| FIGURES IN LAKHS                            |                     |                     |                     |                     |
|---|---------------------|---------------------|---------------------|---------------------|
| <b>Geographical Distribution of Revenue</b> | <b>FY 2022-2023</b> | <b>FY 2021-2022</b> | <b>FY 2020-2021</b> | <b>FY 2019-2020</b> |
| INDIA                                       | 4500.34             | 4345.83             | 3124.63             | 1,701.50            |
| ASIA PACIFIC                                | 466.29              | 1145.97             | 534.24              | 6.48                |
| EUROPE                                      | 4.59                | 63.27               | 5.04                |                     |
| REST OF THE WORLD                           | 0                   | 8.18                | 2.24                |                     |
| <b>TOTAL: -</b>                             | <b>4971.22</b>      | <b>5563.25</b>      | <b>3666.15</b>      | <b>1707.98</b>      |



**SAROJA PHARMA INDUSTRIES INDIA LTD**  
**( FORMERLY KNOWN AS SAROJA PHARMA INDUSTRIES INDIA PVT LTD)**  
**STATEMENTS OF CHANGES IN EQUITY FOR THE YEAR ENDED 31ST MARCH 2023**  
**CIN: U24110MH2019PLC319508**

**NOTE 2**  
**SHARE CAPITAL**

| Particulars  | As at<br>31.03.2023 | As at 31.03.2022 |
|--|---------------------|------------------|
| <b>Authorised</b>  |                     |                  |
| 50,00,000 Equity Shares of Rs.10/- each  |                     | 5,00,00,000      |
| 2,50,000 Equity Shares of Rs.10/- each   |                     | 25,00,000        |
| 10,000 Equity Shares of Rs.10/- each   |                     |                  |
| <b>Issued, Subscribed &amp; Fully Paid-up</b>  | 2,93,56,860         | 22,58,220        |
| <b>FY 2019-20 - 10000 Equity Shares</b> of Rs.10/- each, fully paidup 10,000 Equity Shares of Rs.10/- each, fully paidup 10000 Equity Shares of Rs.10/- each, fully paidup         |                     |                  |
| <b>FY 2020-2021-10000 Equity Shares</b> of Rs.10/- each, fully paidup 10,000 Equity Shares of Rs.10/- each, fully paidup 10000 Equity Shares of Rs.10/- each, fully paidup         |                     |                  |
| <b>FY 2021-2022 - 225822 Equity Shares</b> of Rs.10/- each, fully paidup 10,000 Equity Shares of Rs.10/- each, fully paidup 225822 Equity Shares of Rs.10/- each, fully paidup     |                     |                  |
| <b>FY 2022 - 2023 - 2935686 Equity Shares</b> of Rs.10/- each, fully paidup 10,000 Equity Shares of Rs.10/- each, fully paidup 2935686 Equity Shares of Rs.10/- each, fully paidup |                     |                  |
| <b>Total</b>   | 2,93,56,860         | 22,58,220        |

**NOTE 2A : Reconciliation of the shares outstanding at the beginning and at the end of the reporting period**

| Particulars                                     | As at<br>31.03.2023 | As at 31.03.2022 |
|---|---------------------|------------------|
| Shares outstanding at the beginning of the year | 2,25,822            | 10,000           |
| Shares Issued during the year                   | 27,09,864           | 2,15,822         |
| Shares bought back during the year              |                     |                  |
| Shares outstanding at the end of the year       | 29,35,686           | 2,25,822         |

The Authorised Equity Share Capital of the company was increased from 10,000 Equity Shares of Rs.10/- each to 2,50,000 Equity Shares of Rs. 10/- each vide resolution passed in EGM dated 23/02/2022.

Further Authorised Equity Share Capital of the company was increased from 2,50,000 Equity Shares of Rs.10/- each to 50,00,000 Equity Shares of Rs. 10/- each vide resolution passed in EGM dated 21/12/2022.

The Company issued 15,822 Equity Shares of Rs. 10/- each at Rs. 1106/-converting existing Loan from director into Equity vide Board Resolution dated 28/02/2020.

The Company issued 2,00,000 Equity Shares of Rs. 10/- each for cash at face value vide against Right Issue Board Resolution dated 23/06/2021.

The Company bonus shares issued 27,09,864 Equity Shares of Rs. 10/- each vide Board Resolution dated 08/02/2023.

**NOTE 2B: Term/rights attached to equity shares:**

The Company has only one class of equity shares having a par value of Rs10 per share. Holder of each equity share is entitled to one vote. The Company declares and pays dividends in Indian Rupees. The dividend proposed by the board of directors is subject to the approval of shareholders at the ensuing Annual General Meeting.

In the event of liquidation of the Company, the holders of equity shares will be entitled to receive remaining assets of the Company, after distribution of all preferential amounts. The distribution to equity shareholders will be in proportion to the number of equity shares held

**NOTE 2C : Shares held by promoters at the end of the period**

| Sl. No. | Promoter Name        | % of total shares | As at 31.03.2023 |        | As at 31.03.2022 |        |
|---------|----------------------|-------------------|------------------|--------|------------------|--------|
|         |                      |                   | No. of Shares    | No. of | No. of           | No. of |
| 1       | BIJU GOPINATHAN NAIR | 98.67             | 2896672          |        | 222822           |        |
| 2       | MANISH KAMBLE        | 1.33              | 39000            |        | 3000             |        |
|         | <b>Total</b>         |                   | <b>2935672</b>   |        | <b>225822</b>    |        |





**NOTE 2D : The details of Shareholders holding more than 5% shares:**

| Sl. No | Name of Shareholder  | % of Holding | As at 31.03.2023   | As at 31.03.2022   |  |  |
|--------|----------------------|--------------|--------------------|--------------------|--|--|
|        |                      |              | No. of Shares held | No. of Shares held |  |  |
| 1      | BIJU GOPINATHAN NAIR | 98.67        | 2896672            | 222822             |  |  |
|        |                      |              |                    |                    |  |  |

**NOTE 2E : Holding Company**

|                      |      |
|----------------------|------|
| Name of Company      | N.A. |
| No. of Shares held : | NIL  |
| % of Holding :       | NIL  |

**NOTE 3****RESERVE & SURPLUS**

| Particulars   | As at 31.03.2023   | As at 31.03.2022   |
|---|--------------------|--------------------|
| <b>a. Securities Premium Reserve</b>                          |                    |                    |
| Opening Balance   |                    |                    |
| Add : Securities premium credited on Share issue              | 1,73,40,912        | 1,73,40,912        |
| Less : Bonus Shares issues amount utilised                    | -1,73,40,912       |                    |
| <b>Closing Balance</b>  | -                  | <b>1,73,40,912</b> |
| <b>b. Surplus/(Deficit) in Statement of Profit &amp; Loss</b> |                    |                    |
| Opening balance   | 2,06,60,623        | 92,59,383          |
| Less: Capitalisation of Reserves - Bonus Shares               |                    |                    |
| Add/(Less): Net Profit/(Net Loss) for the current year        | 1,06,06,146        | 1,14,01,240        |
| Less: Bonus Shares issued amount utilised                     | -97,57,728         |                    |
| Less: Deferred Taxes for Earlier Years                        |                    |                    |
| <b>Closing Balance</b>  | <b>2,15,09,041</b> | <b>2,06,60,623</b> |
| <b>Total</b>  | <b>2,15,09,041</b> | <b>2,06,60,623</b> |



**SAROJA PHARMA INDUSTRIES INDIA LTD**  
**( FORMERLY KNOWN AS SAROJA PHARMA INDUSTRIES INDIA PVT LTD)**  
**NOTES FORMING PART OF FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH 2023**  
**CIN: U24110MH2019PLC319508**

**NOTE 4**

**LONG TERM BORROWINGS**

| Particulars                                     | As at 31.03.2023      | As at 31.03.2022      |
|---|-----------------------|-----------------------|
| <b>(i) SECURED LOANS</b>                        |                       |                       |
| <b>Term Loan from Bank:</b>                     |                       |                       |
| Term Loan (refer note-1)                        | 50,00,000.00          | 50,00,000.00          |
| Term Loan (refer note-2)                        | 12,68,860.00          | 18,98,139.00          |
| <b>Term Loan from Financial Institution:</b>    |                       |                       |
|   | <b>62,68,860.00</b>   | <b>68,98,139.00</b>   |
| <b>(ii) UNSECURED LOANS</b>                     |                       |                       |
| Unsecured Loans from Directors (refere note-3)  |                       |                       |
| Note-4 : Unsecured Loan from Bank and Financial |                       |                       |
| a) Axis Bank                                    | 13,82,505.00          | 23,45,663.00          |
| b) Bajaj Finance Ltd                            | 14,68,628.00          | 23,82,928.00          |
| c) Bajaj Finance Ltd                            | 27,69,068.00          |                       |
| d) Fullerton India Credit                       | 40,85,202.81          |                       |
| e) ICICI Bank                                   | 15,09,519.00          | 24,60,258.00          |
| f) IDFC First Bank Ltd                          | 58,51,095.18          |                       |
| g) Tata Capital                                 | 47,80,309.00          | 28,84,152.00          |
| <b>Total (i)+(ii)</b>                           | <b>2,18,46,326.99</b> | <b>1,00,73,001.00</b> |
| <b>Total (i) + (ii)</b>                         | <b>2,81,15,186.99</b> | <b>1,69,71,140.00</b> |

| Particulars  | Nature of Loan                            | Term of Repayment  |        |
|--|---|--|--------|
| <b>Details of Secured Loans from Bank :-</b>                 |   |  |        |
| Note-1 : Secured Term Loan from Bank of Baroda Mulund Branch | Term Loan for an amount of Rs.50.00 Lakhs | Repayable in 36 equated monthly installements of Rs. 1.38 Lakhs starting from Jan.24. ((Initial loan sanction date | 9.25%  |
| Note-2 : Secured car Loan from Saraswat. Mulund Branch       | Term Loan on Vehicle-20L                  | Repayable in 36 equated monthly installements of Rs. 0.61 Lakhs starting from Feb.22.                              | 6.75%  |
| Note-3 : Unsecured car Loan from Director                    |   | Repayable on Demand  | 10.10% |
| <b>Note-4 : Unsecured Loan from Financial Institution</b>    |   |  |        |
| a). Axis Bank  | Term Loan on-30L                          | Repayable in 36 equated monthly installements of Rs. 1.01 Lakhs starting from jul 2021.                            | 13.50% |
| b) Bajaj Finance Ltd   | Term Loan on-29.19 L                      | Repayable in 36equated monthly installements of Rs. 1.02 Lakhs starting from jul 2021.                             | 16.00% |



*[Handwritten Signature]*

|   |                      |   |                  |
|---|----------------------|---|------------------|
| c) Bajaj Finance Ltd                          | Term Loan on-28.92 L | Repayable in 36equated monthly installements of Rs. 1.04 Lakhs starting from jul 2021.  | 17.75%           |
| d) Fullerton India Credit                     | Term Loan on-50L     | Repayable in 36equated monthly installements of Rs. 1.76 Lakhs starting from jul 2021.  | 16.00%           |
| e) ICICI Bank                                 | Term Loan on-30L     | Repayable in 36 equated monthly installements of Rs. 1.05 Lakhs starting from jul 2021. | 15.00%           |
| f) IDFC First Bank Ltd                        | Term Loan on-61.20 L | Repayable in 36 equated monthly installements of Rs. 2.15 Lakhs starting from jul 2021. | 16.00%           |
| g) Tata Capital                               | Term Loan on-50L     | Repayable in 36 equated monthly installements of Rs. 1.76 Lakhs starting from jul 2021. | 16.00%           |
| <b>NOTE 5</b>                                 |                      |   |                  |
| <b>DEFERRED TAX ASSETS /(LIABILITIES) NET</b> |                      |   |                  |
| <b>Particulars</b>                            |                      | <b>2022-23</b>  | <b>2021-2022</b> |
| Deprcciation as per Companies Act, 2013       |                      | 27,33,792   | 33,06,697        |
| Deprcciation as per Income Tax Act, 1961      |                      | 31,86,609   | 34,41,846        |
| <b>Differential Net Timing Difference</b>     | [A]                  | -4,52,817   | -1,35,149        |
| Unabsorbed Losses                             | [B]                  | -   | -                |
| Provision for Gratuity                        | [C]                  | -   | -                |
| Substantively Enacted Tax Rate                | [D]                  | 27.82%  | 25.00%           |
| <b>Net Deferred Tax</b>                       |                      | <b>-125973.69</b>   | <b>-33787.25</b> |
| <b>[(A+B+C) X D]</b>                          |                      |   |                  |



| Particulars  |  | As at 31.03.2023  | As at 31.03.2022   |
|--|--|---|--------------------|
| <b>Opening Balance</b>   |  | -33,787.0   | -17,918.0          |
| <b>Add: Taken over</b>   |  |   |                    |
| <b>Less: Prior Period Adjustments</b>  |  |   |                    |
| <b>Add: Additions During the Year</b>  |  |   |                    |
| a. Fixed assets: Impact of difference between tax depreciation and depreciation/ amortization charged for the financial reporting. |  | -92,187.0   | -15,869.0          |
| <b>Total</b>   |  | <b>-1,25,974.0</b>  | <b>-33,787.0</b>   |
| <b>NOTE 6</b>  |  |   |                    |
| <b>SHORT TERM BORROWINGS</b>   |  |   |                    |
| Particulars  |  | As at 31.03.2023  | As at 31.03.2022   |
| <b>Secured</b>   |  |   |                    |
| Working capital loan (refer note-1)  |  |   | 4,44,16,362        |
| Working capital loan (refer note-2)  |  | 7,37,71,311   |                    |
| <b>Unsecured</b>   |  |   |                    |
| <b>Repayable on demand</b>   |  |   |                    |
| From Related Parties   |  |   |                    |
| From Others  |  |   |                    |
| Current Maturities of Long Term debt   |  |   |                    |
| <b>Total</b>   |  | <b>7,37,71,311</b>  | <b>4,44,16,362</b> |
| <b>Details of Secured Loans from Bank :-</b>   |  |   |                    |
| Note-1: Secured Loan from Saraswat Bank, Mulund Branch   | OCC/ODBD for an amount of Rs.600 Lakhs | 1) Hypothication of Stock and Book Debts.<br>2) Having Collateral security on Director properties<br>a) 305, Kailash Tower, Shiv Shrishti Complex, Goregaon Link Road, Mulund West Mumbai 400 080 and<br>b) Flat no 504, Building no 1, Surya Enclave CHSL, Chitalsar, Manpada, Thane west<br>c) House 41, Perumbavoor, Kerala<br>3) Pledged FD for an amount of Rs.25L.<br>PLR - 4.25% i.e 9.75%   |                    |
| Note-2: Secured Loan from Bank of Baroda, Veenanagar Branch  | OCC/ODBD for an amount of Rs.700 Lakhs | 1) Hypothication of Stock and Book Debts.<br>2) Having Collateral security on Director properties<br>a) 305, Kailash Tower, Shiv Shrishti Complex, Goregaon Link Road, Mulund West Mumbai 400 080 and<br>b) Flat no 504, Building no 1, Surya Enclave CHSL, Chitalsar, Manpada, Thane west<br>c) House 41, Perumbavoor, Kerala<br>3) Pledged FD for an amount of Rs.25L.<br>4) Plant & Machinery & Office Equipment<br>BR + 2.2 % = 7.45% |                    |



**SAROJA PHARMA INDUSTRIES INDIA LTD**  
**( FORMERLY KNOWN AS SAROJA PHARMA INDUSTRIES INDIA PVT LTD)**  
**NOTES FORMING PART OF FINANCIAL STATEMENT FOR THE YEAR ENDED 31ST**  
**MARCH 2023.**

CIN: U24110MH2019PLC319508

**NOTE 7**

**TRADE PAYABLES**

| Particulars                        | As at 31.03.2023   | As at 31.03.2022   |
|------------------------------------|--------------------|--------------------|
| Micro, Small and Medium Enterprise | 3,77,27,630        | 2,69,67,152        |
| From Others                        | 2,09,01,964        | 2,60,84,780        |
| <b>Total</b>                       | <b>5,86,29,594</b> | <b>5,30,51,932</b> |

**For 31.03.2023**

| Particulars                | Outstanding for following periods from due |           | Total       |
|----------------------------|--|-----------|-------------|
|                            | < 1 Year                                   | 1-2 Years |             |
| (i) MSME                   | 3,77,27,630                                |           | 3,77,27,630 |
| (ii) Others                | 2,09,01,964                                | -         | 2,09,01,964 |
| (iii) Disputed Dues-MSME   |  |           |             |
| (iii) Disputed Dues-Others |  |           |             |

**For 31.03.2022**

| Particulars                | Outstanding for following periods from due |           | Total       |
|----------------------------|--|-----------|-------------|
|                            | < 1 Year                                   | 1-2 Years |             |
| (i) MSME                   | 2,69,67,152                                |           | 2,69,67,152 |
| (ii) Others                | 2,60,84,780                                | -         | 2,60,84,780 |
| (iii) Disputed Dues-MSME   |  |           |             |
| (iii) Disputed Dues-Others |  |           |             |

**NOTE 8**

| Particulars                    | As at 31.03.2023 | As at 31.03.2022 |
|--------------------------------|------------------|------------------|
| Statutory Dues                 | 1,25,806         | 2,41,694         |
| Other Current Liabilities      |                  |                  |
| <b>Other Advances</b>          |                  |                  |
| From Related Parties           |                  |                  |
| From Others                    |                  |                  |
| Advance from Customers         |                  |                  |
| Advance from directors         |                  |                  |
| Expenses Payable               | 47,222           |                  |
| Staff Salary and wages Payable |                  |                  |
| <b>Total</b>                   | <b>1,73,028</b>  | <b>2,41,694</b>  |

**NOTE 9**

**SHORT TERM PROVISION**

| Particulars              | As at 31.03.2023 | As at 31.03.2022 |
|--------------------------|------------------|------------------|
| Provision for Income Tax | 17,17,638        |                  |
| Other Provisions Payable |                  | 1,44,177         |
| Provision for Bad Debts  |                  |                  |
| <b>Total</b>             | <b>17,17,638</b> | <b>1,44,177</b>  |






**SAROJA PHARMA INDUSTRIES INDIA LTD**  
( FORMERLY KNOWN AS SAROJA PHARMA INDUSTRIES INDIA PVT LTD)  
CIN- U24110MH2019PLC319508

**NOTES FORMING PART OF FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH 2023**

**NOTE - 10**  
**Property, Plant & Equipment & Intangible Assets**

| Particulars                      | Gross Block         |                     |                     | Depreciation    |                     |                     |
|----------------------------------|---------------------|---------------------|---------------------|-----------------|---------------------|---------------------|
|                                  | As at<br>01.04.2022 | As at<br>31.03.2023 | As at<br>01.04.2022 | For the year    | As at<br>31.03.2023 | As at<br>31.03.2022 |
| <b>Tangible Assets</b>           |                     |                     |                     |                 |                     |                     |
| Land At Sinnar, Nashik           |                     | 1,89,65,000         |                     |                 |                     |                     |
| Computer                         | 6,32,368            | 6,32,368            | 3,21,480            | 1,37,964        | 4,59,444            | 1,89,65,000         |
| Furniture & Fixtures             | 2,17,000            | 2,17,000            | 45,709              | 20,615          | 66,324              | 1,72,925            |
| Mobile Phone                     | 4,21,599            | 7,63,306            | 2,00,529            | 1,36,306        | 3,36,835            | 1,50,676            |
| Motor Vehicle                    | 24,12,413           | 24,12,413           | 49,702              | 2,29,179        | 2,78,881            | 4,26,471            |
| Electronic Equipments            | 3,20,987            | 3,20,987            | 9,747               | 1,01,646        | 1,11,393            | 21,33,532           |
| Office Equipment                 | 50,245              | 1,19,769            | 19,220              | 22,756          | 41,976              | 2,09,594            |
| camera                           | 34,362              | 34,362              | 26,324              | 6,320           | 32,644              | 77,793              |
| <b>Total</b>                     | <b>40,88,974</b>    | <b>2,34,65,205</b>  | <b>6,72,711</b>     | <b>6,54,786</b> | <b>13,27,497</b>    | <b>2,21,37,708</b>  |
| <b>Intangible Assets</b>         |                     |                     |                     |                 |                     |                     |
| Software                         | 87,500              | 87,500              | 61,917              | 11,682          | 73,599              | 13,901              |
| <b>Grand Total</b>               | <b>41,76,474</b>    | <b>2,35,52,705</b>  | <b>7,34,628</b>     | <b>6,66,468</b> | <b>14,01,096</b>    | <b>2,21,51,609</b>  |
| <b>Capital Work-in Progress#</b> | <b>1,78,87,716</b>  | <b>1,78,87,716</b>  |                     |                 |                     | <b>1,78,87,716</b>  |

| Particulars                  | Gross Block         |                     |                     | Depreciation    |                     |                     |
|------------------------------|---------------------|---------------------|---------------------|-----------------|---------------------|---------------------|
|                              | As at<br>01.04.2021 | As at<br>31.03.2022 | As at<br>01.04.2021 | For the year    | As at<br>31.03.2022 | As at<br>31.03.2021 |
| <b>Tangible Assets</b>       |                     |                     |                     |                 |                     |                     |
| Computer                     | 3,38,969            | 6,32,368            | 1,17,796            | 2,03,684        | 3,21,480            | 3,10,889            |
| Furniture & Fixtures         | 2,17,000            | 2,17,000            | 25,094              | 20,615          | 45,709              | 1,71,291            |
| Mobile Phone                 | 3,76,599            | 4,21,599            | 77,998              | 1,22,531        | 2,00,529            | 2,21,070            |
| Motor Vehicle                | 66,676              | 24,12,413           | 7,346               | 42,356          | 49,702              | 23,62,711           |
| <b>ELECTRONIC EQUIPMENTS</b> |                     |                     |                     |                 |                     |                     |
| Office Equipment             | 50,245              | 50,245              | 9,674               | 9,747           | 3,11,240            | 59,330              |
| camera                       | 34,362              | 34,362              | 15,443              | 10,881          | 19,220              | 31,025              |
| <b>Total</b>                 | <b>10,83,851</b>    | <b>40,88,974</b>    | <b>2,53,351</b>     | <b>4,19,360</b> | <b>6,72,711</b>     | <b>8,30,500</b>     |
| <b>Intangible Assets</b>     |                     |                     |                     |                 |                     |                     |
| Software                     | 69,500              | 87,500              | 25,012              | 36,905          | 61,917              | 25,583              |
| <b>Grand Total</b>           | <b>11,53,351</b>    | <b>41,76,474</b>    | <b>2,78,363</b>     | <b>4,56,265</b> | <b>7,34,628</b>     | <b>8,74,988</b>     |



*(Signature)*

**SAROJA PHARMA INDUSTRIES INDIA LTD**  
**( FORMERLY KNOWN AS SAROJA PHARMA INDUSTRIES INDIA PVT LTD)**  
**NOTES FORMING PART OF FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH 2023**  
**CIN: U24110MH2019PLC319508**

**NOTE 11**

**NON CURRENT INVESTMENT**

| Particulars | As at 31.03.2023 | As at 31.03.2022 |
|-------------|------------------|------------------|
| Gold Coins  | 13,94,059        | 3,67,166         |
| Shares      | 25,000           | 25,000           |
|             | <b>14,19,059</b> | <b>3,92,166</b>  |

**NOTE 12**

**LONG TERM LOANS AND ADVANCES**

| Particulars                  | As at 31.03.2023   | As at 31.03.2022 |
|------------------------------|--------------------|------------------|
| <b>a. Capital Advances</b>   |                    |                  |
| (Unsecured, considered good) |                    |                  |
| To Staff Loan & Advance      | -                  |                  |
| To Advance for Factory plot  | 1,01,40,100        |                  |
| <b>b. Security Deposit</b>   |                    |                  |
| (Unsecured, considered good) |                    |                  |
| Rent                         | 3,09,130           | 3,66,600         |
| Gold Coins                   |                    |                  |
| Shares                       |                    |                  |
| <b>Total</b>                 | <b>1,04,49,230</b> | <b>3,66,600</b>  |

**NOTE 13 INVENTORIES**

| Particulars                               | As at 31.03.2023   | As at 31.03.2022 |
|---|--------------------|------------------|
| (As Valued & certified by the Management) |                    |                  |
| Raw-materials                             |                    |                  |
| Finished Goods                            | 3,86,58,224        | 46,65,229        |
| <b>Total</b>                              | <b>3,86,58,224</b> | <b>46,65,229</b> |



| <b>NOTE 14</b>                    |                         |                         |
|-----------------------------------|-------------------------|-------------------------|
| <b>TRADE RECEIVABLES</b>          |                         |                         |
| <b>Particulars</b>                | <b>As at 31.03.2023</b> | <b>As at 31.03.2022</b> |
| <b>Unsecured, considered good</b> |                         |                         |
| Trade Receivables                 | 11,10,78,412            | 13,97,98,544            |
| <b>Total</b>                      | <b>11,10,78,412</b>     | <b>13,97,98,544</b>     |

| <b>PARTICULARS</b>                                     | <b>Ageing Schedule of Trade Receivable - as at 31-03-2023</b> |                         |                |              |
|--|---|-------------------------|----------------|--------------|
|  | <b>Less than 6 months</b>                                     | <b>6 months- 1 year</b> | <b>1-2 yrs</b> | <b>Total</b> |
| i. Undisputed Trade receivables - considered good      | 11,01,86,875  | 6,25,665                |                | 11,08,12,540 |
| ii. Undisputed Trade Receivables - considered doubtful |   |                         |                |              |
| iii. Disputed Trade Receivables considered good        |   |                         | 2,65,872       | 2,65,872     |
| iv. Disputed Trade Receivables considered              |   |                         |                |              |

| <b>PARTICULARS</b>                                     | <b>Ageing Schedule of Trade Receivable - as at 31st Mar'22</b> |                         |                |              |
|--|--|-------------------------|----------------|--------------|
|  | <b>Less than 6 months</b>                                      | <b>6 months- 1 year</b> | <b>1-2 yrs</b> | <b>Total</b> |
| i. Undisputed Trade receivables - considered           | 13,61,45,737   | 86,935                  |                | 13,62,32,672 |
| ii. Undisputed Trade Receivables - considered doubtful |  |                         |                |              |
| iii. Disputed Trade Receivables considered good        |  | 35,65,872               |                | 35,65,872    |
| iv. Disputed Trade Receivables considered              |  |                         |                |              |
| iv. Disputed Trade Receivables considered              |  |                         |                |              |

| <b>NOTE 15</b>  |                         |                         |
|---|-------------------------|-------------------------|
| <b>CASH AND CASH EQUIVALENTS</b>                        |                         |                         |
| <b>Particulars</b>                                      | <b>As at 31.03.2023</b> | <b>As at 31.03.2022</b> |
| a. Balances with banks                                  |                         |                         |
| - Current Accounts                                      | 15,318                  | 42,432                  |
| Other Bank Balance - (Recurring Deposit & Term Deposit) | 34,07,494               | 25,94,308               |
| b. Cash on hand (As certified by the management)        | 2,18,507                | 9,621                   |
| <b>Total</b>  | <b>36,41,319</b>        | <b>26,46,361</b>        |



**SAROJA PHARMA INDUSTRIES INDIA LTD**  
**( FORMERLY KNOWN AS SAROJA PHARMA INDUSTRIES INDIA PVT LTD)**  
**NOTES FORMING PART OF FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST**  
**MARCH 2023**  
**CIN: U24110MH2019PLC319508**

**NOTE 16**

**SHORT TERM LOANS AND ADVANCES**

| Particulars   | As at 31.03.2023 | As at 31.03.2022 |
|---|------------------|------------------|
| <b>(Unsecured, considered good)</b>                             |                  |                  |
| <b>a. Loans</b>   |                  |                  |
| To Related Parties  |                  |                  |
| <b>(Recoverable in Cash or in Kind or value to be received)</b> |                  |                  |
| <b>a. Advances</b>  |                  |                  |
| Advance to Suppliers  |                  |                  |
| Advance to Staff  | 2,57,500         | 2,66,100         |
| Advance for Land purchase                                       |                  | 22,00,000        |
| Advance to Others   | 1,84,946         |                  |
| Advance tax   |                  |                  |
| <b>Total</b>  | <b>4,42,446</b>  | <b>24,66,100</b> |

**NOTE 17**

**OTHER CURRENT ASSETS**

| Particulars                  | As at 31.03.2023 | As at 31.03.2022 |
|------------------------------|------------------|------------------|
| Deposits                     |                  |                  |
| Duty Drawback Receivables    | 8,288            | 98,525           |
| GST Debit Balance            | 54,70,944        | 4,94,316         |
| GST Refund                   | 35,632           | 35,632           |
| Income Tax Refund            | -                | 1,16,990         |
| Margin Money Receivables     | -                | 9,779            |
| Prepaid expenses             | 3,45,754         | 4,78,014         |
| Priliminary Expenses         | 18,10,000        |                  |
| Provision for Forex Exchange | -                | 1,01,997         |
| TCS Receivables              | -                | 6,748            |
| <b>Total</b>                 | <b>76,70,618</b> | <b>13,42,001</b> |

**NOTE 18**

**REVENUE FROM OPERATIONS**

| Particulars             | For the year ended 31.03.2023 | For the year ended 31.03.2022 |
|-------------------------|-------------------------------|-------------------------------|
| <b>Sale of Products</b> |                               |                               |
| Sales                   | 49,71,21,562                  | 55,63,25,325                  |
| Consultancy Service     | 48,10,000                     |                               |
| <b>Total</b>            | <b>50,19,31,562</b>           | <b>55,63,25,325</b>           |



*[Handwritten signature]*



**NOTE 19****OTHER INCOME**

| Particulars                              | For the year ended 31.03.2023 | For the year ended 31.03.2022 |
|--|-------------------------------|-------------------------------|
| <b>Recurring and Related to Business</b> |                               |                               |
| Dividend                                 | 5,015                         | 5,000                         |
| Duty Drawback Income                     | 6,05,996                      | 15,67,955                     |
| Gain On Foreign Exchange Rate            | 8,42,321                      | 15,74,578                     |
| Interest on Tax refund                   |                               | 750                           |
| Interest on Term Deposit                 | 1,23,736                      | 93,502                        |
|  | <b>15,77,068</b>              | <b>32,41,785</b>              |

**NOTE 20****COST OF MATERIALS CONSUMED**

| Particulars                    | For the year ended 31.03.2023 | For the year ended 31.03.2022 |
|--------------------------------|-------------------------------|-------------------------------|
| Opening Stock of Raw Materials |                               |                               |
| Add: Purchases                 | 47,71,37,999                  | 48,31,50,992                  |
| Direct Expense                 | 98,14,466                     | 1,81,59,718                   |
| <b>Total</b>                   | <b>48,69,52,465</b>           | <b>50,13,10,710</b>           |

**NOTE 21****(INCREASE) / DECREASE IN INVENTORIES**

| Particulars                           |                     |                  |
|---------------------------------------|---------------------|------------------|
| Closing Stock of Finished Goods       | -3,86,58,224        | -46,65,229       |
| Less: Opening Stock of Finished Goods | 46,65,229           | 65,61,000        |
| <b>Total</b>                          | <b>-3,39,92,995</b> | <b>18,95,771</b> |



A handwritten signature in blue ink, appearing to be "S. J.", located to the right of the Sarola Pharma stamp.

**SAROJA PHARMA INDUSTRIES INDIA LTD**  
**( FORMERLY KNOWN AS SAROJA PHARMA INDUSTRIES INDIA PVT LTD)**  
**NOTES FORMING PART OF FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST**  
**MARCH 2023**  
**CIN: U24110MH2019PLC319508**

**NOTE 22**

**EMPLOYEES BENEFITS EXPENSE**



| Particulars             | For the year ended<br>31.03.2023 | For the year ended<br>31.03.2022 |
|-------------------------|----------------------------------|----------------------------------|
| Bonus                   | 4,10,000                         | 4,65,500                         |
| Director's Remuneration | 54,00,000                        | 41,60,000                        |
| Staff Welfare Expense   | 80,006                           | 1,10,005                         |
| Salaries & Wages        | 77,86,000                        | 66,93,150                        |
| <b>Total</b>            | <b>1,36,76,006</b>               | <b>1,14,28,655</b>               |

**NOTE 23 FINANCE COST**

| Particulars                     | For the year ended<br>31.03.2023 | For the year ended<br>31.03.2022 |
|---------------------------------|----------------------------------|----------------------------------|
| Interest on OD Account          | -                                | -                                |
| Interest on Cash Credit Account | 70,98,808                        | 39,41,730                        |
| Interest Paid on Loans          | 23,77,665                        | 26,46,616                        |
| Interest on Term Loan(GECL)     | 4,68,229                         | 65,890                           |
| Other Finance Charges           | 32,44,110                        | 13,59,061                        |
| <b>Total</b>                    | <b>1,31,88,812</b>               | <b>80,13,297</b>                 |

**NOTE 24**

| Particulars                  | For the year ended<br>31.03.2023 | For the year ended<br>31.03.2022 |
|------------------------------|----------------------------------|----------------------------------|
| Amount W/off                 | 9,286                            | 34,529                           |
| Auditors Remuneration *      | 50,000                           | 40,000                           |
| Business Promotion           | 11,42,291                        | 12,02,751                        |
| Commission                   | 12,29,477                        | 1,46,75,256                      |
| Computer Expenses            | 48,643                           | 39,409                           |
| Conveyance Expenses          | 5,27,279                         | 5,14,989                         |
| Courier Expenses             | 89,741                           | 89,847                           |
| Discounts allowed            | -1,575                           | 40                               |
| Diwali Expenses              | 1,90,917                         | 1,96,740                         |
| Electricity charges          | 3,41,623                         | 68,250                           |
| Export Expenses              | 10,41,482                        |                                  |
| Godown Cleaning Charges      | 97,419                           | 9,730                            |
| Insurance                    | 4,62,537                         | 6,31,901                         |
| Interest on TDS/GST          | 8,340                            | 7,209                            |
| Laboratories Expenses        | -                                | 2,67,978                         |
| Legal & Professional Charges | 4,73,313                         | 4,59,800                         |
| Office expenses              | 1,04,465                         | 1,23,057                         |
| Office Rent                  | 7,50,870                         | 7,25,400                         |




|   |  |  |
|---|--|--|
| Printing & Stationery                               | 73,193                                   | 93,661                                   |
| Processing Fees                                     |  | 2,66,330                                 |
| Profession Tax - Company                            | 7,500                                    | 7,500                                    |
| Rent, Rates & Taxes                                 | 2,62,320                                 | 96,000                                   |
| Repairs & Maintenance                               | 4,100                                    | 3,14,689                                 |
| Round Off   | -1                                       | 10                                       |
| Tea & Refreshment Expenses                          | 82,833                                   | 66,100                                   |
| Telephone and Internet Charges                      | 1,09,847                                 | 68,273                                   |
| Travelling Expenses                                 | 4,93,978                                 | 5,52,026                                 |
| Vehicle Expenses                                    | 3,30,346                                 | 1,17,850                                 |
| Warehousing Handling Charges                        | 1,72,600                                 |  |
| <b>Total</b>  | <b>81,02,824</b>                         | <b>2,06,69,325</b>                       |
| <b>*Details of Payment to Auditors &amp; Others</b> |  |  |
| <b>Particulars</b>                                  | <b>For the year ended<br/>31.03.2023</b> | <b>For the year ended<br/>31.03.2022</b> |
| Payments to the auditors:                           |  |  |
| Statutory Audit                                     | 50,000                                   | 40,000                                   |
| Certification Charges                               |  |  |
| Payments to others:                                 |  |  |
| Restated financials preparation charges             |  |  |
| <b>Total</b>  | <b>50,000</b>                            | <b>40,000</b>                            |



**SAROJA PHARMA INDUSTRIES INDIA LTD**  
**( FORMERLY KNOWN AS SAROJA PHARMA INDUSTRIES INDIA PVT LTD)**  
**NOTES FORMING PART OF FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH**  
**2023**  
**CIN: U24110MH2019PLC319508**

**NOTE 25- BASIC AND DILUTED EARNINGS PER SHARE**

| Particulars                                 |      | 2022-23     | 2021-2022   |
|---|------|-------------|-------------|
| Profit after Tax                            | Rs.  | 1,06,06,148 | 1,14,01,240 |
| Present Number of equity shares of Rs. 10/- | Nos. | 29,35,672   | 2,25,822    |
| Weighted average number of Equity shares    | Nos. | 6,04,461    | 1,65,908    |
| Basic earnings per share                    | Rs.  | 17.55       | 68.72       |
| Diluted Earning per Share                   | Rs.  | 17.55       | 68.72       |





**SAROJA PHARMA INDUSTRIES INDIA LTD**  
**( FORMERLY KNOWN AS SAROJA PHARMA INDUSTRIES INDIA PVT LTD)**  
**NOTES FORMING PART OF FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH**  
**2023**

CIN: U24110MH2019PLC319508

**NOTE 26 -STATEMENT OF RELATED PARTY TRANSACTIONS**

**A. List of Related parties**

| <u>Sl. No.</u>                        | <u>Name</u>             | <u>Relation</u>   |
|---------------------------------------|-------------------------|-------------------|
| <b><u>Key Mangerial Personnel</u></b> |                         |                   |
| 1                                     | Biju Gopinathan Nair    | Managing Director |
| 2                                     | Manish Dasharath Kamble | WholetimeDirector |

**Relative of Key Mangerial Personnel**

NIL

**Enterprises having Significant Influence**

NIL

**AS ON 31.03.2023**


| <b>A. Transactions with Related Parties during the year</b> | <b>Amount in Lakhs</b> |
|---|------------------------|
| Nature of Transactions                                      |                        |
| Remuneration Paid to Biju G Nair                            | 38,40,000              |
| Remuneration Paid to Manish D Kamble                        | 15,60,000              |
| Loan Taken  |                        |
| Loan Taken Refunded   |                        |
| Loan Given  |                        |
| Loan refund received  |                        |

| <b>B. Outstanding Balances</b> | <b>Amount in Lakhs</b> |
|--------------------------------|------------------------|
| Nature of Transactions         |                        |
| Remuneration Payable           |                        |
| Loan Taken                     |                        |
| Loan Given                     |                        |

**AS ON 31.03.2022**

| <b>A. Transactions with Related Parties during the year</b> | <b>Amount in Lakhs</b> |
|---|------------------------|
| Nature of Transactions                                      |                        |
| Remuneration Paid to Biju G Nair                            | 29,00,000              |
| Remuneration Paid to Manish D Kamble                        | 12,60,000              |
| Loan Taken from Biju G Nair                                 | 1,53,35,601            |
| Loan Taken from Manish D Kamble                             | 37,55,000              |
| Loan Taken Refunded to Biju G Nair                          | 2,77,97,193            |
| Loan Taken Refunded to Manish D Kamble                      | 54,55,000              |
| Loan Given  |                        |
| Loan refund received  | -                      |

| <b>B. Outstanding Balances</b> | <b>Amount in Lakhs</b> |
|--------------------------------|------------------------|
| Nature of Transactions         |                        |
| Remuneration Payable           |                        |
| Loan Taken                     |                        |
| Loan Given                     | -                      |




*[Handwritten Signature]*

**SAROJA PHARMA INDUSTRIES INDIA LTD**  
**( FORMERLY KNOWN AS SAROJA PHARMA INDUSTRIES INDIA PVT LTD)**  
**NOTES FORMING PART OF FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH 2023**  
**CIN: U24110MH2019PLC319508**

**NOTE 27: RATIOS**

| Particulars   | As at 31.03.2023 | As at 31.03.2022 |
|---|------------------|------------------|
| Current Assets [A]                                      | 16,14,91,019.00  | 15,09,18,235.00  |
| Current Liabilities [B]                                 | 13,42,91,571.00  | 9,78,54,165.00   |
| <b>Current Ratio [A / B]</b>                            | <b>1.20</b>      | <b>1.54</b>      |
| Debt [A]  | 10,18,86,497.99  | 6,13,87,502.00   |
| Equity [B]  | 5,08,65,901.00   | 4,02,59,755.00   |
| <b>Debt - Equity Ratio [A / B]</b>                      | <b>2.00</b>      | <b>1.52</b>      |
| Earnings available for debt [A]                         | 28770330.00      | 24262649.00      |
| Debt Service [B]  | 13188812.00      | 8013297.00       |
| <b>Debt - Service Coverage Ratio [A / B]</b>            | <b>2.18</b>      | <b>3.03</b>      |
| Net Profit after Tax [A]                                | 10606148.00      | 11401240.00      |
| Average Shareholder's Equity [B]                        | 72124888.50      | 44989446.50      |
| <b>Return on Equity Ratio [A / B]</b>                   | <b>0.15</b>      | <b>0.25</b>      |
| Cost of Goods Sold [A]                                  | 452959470.00     | 503206481.00     |
| Average Inventory [B]                                   | 21661726.50      | 5613114.50       |
| <b>Inventory Turnover Ratio [A / B]</b>                 | <b>20.91</b>     | <b>89.65</b>     |
| Net Credit Sales [A]                                    | 501931562.00     | 556325325.00     |
| Average Trade Receivables [B]                           | 125438478.00     | 106016839.00     |
| <b>Trade Receivables Turnover Ratio [A / B]</b>         | <b>4.00</b>      | <b>5.25</b>      |
| Net Credit Purchase [A]                                 | 477137999.00     | 483150992.00     |
| Average Trade Payables [B]                              | 55840763.00      | 47277187.50      |
| <b>Trade Payables Turnover Ratio [A / B]</b>            | <b>8.54</b>      | <b>10.22</b>     |
| Net Sales [A]   | 501931562.00     | 556325325.00     |
| Current Assets  | 16,14,91,019.00  | 15,09,18,235.00  |
| Current Liabilities                                     | 134291571.00     | 97854165.00      |
| Working Capital   | 27199448.00      | 53064070.00      |
| Average Working Capital [B]                             | 40131759.00      | 37698687.50      |
| <b>Net Capital Turnover Ratio [A / B]</b>               | <b>12.51</b>     | <b>14.76</b>     |
| Net Profit [A]  | 10606148.00      | 11401240.00      |
| Net Sales [B]   | 501931562.00     | 556325325.00     |
| <b>Net Profit Ratio [A / B]</b>                         | <b>0.02</b>      | <b>0.02</b>      |
| Earning before interest and taxes [A]                   | 2,81,03,862.00   | 2,38,06,384.00   |
| Capital Employed [B]                                    | 11,13,86,161.48  | 9,36,97,558.47   |
| Capital Employed = Total Assets + Total Debt + Deffered |                  |                  |
| <b>Return on Capital Employed [A / B]</b>               | <b>0.25</b>      | <b>0.25</b>      |



**SAROJA PHARMA INDUSTRIES INDIA LTD**  
**( FORMERLY KNOWN AS SAROJA PHARMA INDUSTRIES INDIA PVT LTD)**  
**NOTES FORMING PART OF FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST**  
**MARCH 2023**  
**CIN: U24110MH2019PLC319508**

**NOTE 28 -CONTIGENT LIABILITIES**

| Particulars  | As at 31.03.2023 | As at 31.03.2022 |
|--|------------------|------------------|
| Claims against the company not acknowledged as Debts   | Unascertainable  | Unascertainable  |
| Bank Guarantee (Financial)   | NIL              | NIL              |
| Bank Guarantee (Performance)   | NIL              | NIL              |
| Income Tax Demand  | NIL              | NIL              |
| TDS Demand   | NIL              | NIL              |
| Sales Tax Pending Cases  | NIL              | NIL              |
| GST contingent liability on account of mismatch in 2A, 2B and 3B                               | NIL              | NIL              |
| Other moneys for which the Company is contingently   | NIL              | NIL              |
| Commitments (to the extent not provided for)   | NIL              | NIL              |
| Estimated amount of contracts remaining to be executed on capital account and not provided for | NIL              | NIL              |
| Uncalled liability on shares and other investments partly paid                                 | NIL              | NIL              |
| Other commitments  | NIL              | NIL              |
| <b>Total</b>   |                  |                  |

**NOTE 29**

Previous year figures have been recasted / restated where necessary.

**Significant Accounting Policies & Notes on Accounts**

For Pravin Chandak & Associates

Chartered Accountant

Firm Regn No: 116627W

Pravin Chandak

Partner

Membership No.:049391

Place: Mumbai

Date: 17/05/2023

For & on behalf of the Board of Directors

SAROJA PHARMA INDUSTRIES INDIA LTD  
(FORMERLY KNOWN AS SAROJA PHARMA  
INDUSTRIES INDIA PVT LTD)

*Biju G Nair*

Biju G Nair  
Managing Director  
DIN: 08330223

*Manish D Kamble*

Manish D Kamble  
Wholetime Director  
DIN: 08330224

